A Phase Ib Dose De-escalation Study of the Combination of Tamoxifen Plus Goserelin Acetate With Alpelisib (BYL719) or Buparlisib (BKM120) in Premenopausal Patients With Hormone Receptor-positive/HER2-negative Locally Advanced or Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2018
Price : $35 *
At a glance
- Drugs Alpelisib (Primary) ; Buparlisib (Primary) ; Goserelin; Tamoxifen
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms B-YOND
- Sponsors Novare Pharmaceuticals; Novartis
- 12 Oct 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2018 Planned End Date changed from 30 Apr 2018 to 20 Jun 2018.
- 10 Jun 2018 Planned primary completion date changed from 30 Apr 2018 to 15 Jun 2018.